Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director | September 16, 2024 | September 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emmaus Life Sciences, Inc.
Report date September 16, 2024 · Filed September 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.001 par valueSEC Table I · non-derivative | Direct | 4,606,626 |
Reported balance
After 2024-09-16 transaction · row 1
1 source rowRow 1 · 2024-09-16 · Purchase · Acquired 20,000 · Balance 4,606,626 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2024 Filed Sep 18, 2024 15:40 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 20,000 | $0.04 | $800.00 |
DisclosureSEC source: 0000950170-24-107658 · ownership.xml · nonDerivative · entry 1 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,606,626 Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 21:38 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | GrantOptions · Derivative | 100,000 | $0.15 Strike: $0.15 | $15,000.00 |
DisclosureSEC source: 0001209191-24-002811 · doc4.xml · derivative · entry 1 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: The options vest in four equal installments as of the last day of each quarter beginning on March 31, 2024 Read SEC document |
| December 20, 2023 Filed Dec 21, 2023 16:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | SaleCommon stock, $0.001 par value | 32,500 | $0.05 | $1,625.00 |
DisclosureSEC source: 0001209191-23-059399 · doc4.xml · nonDerivative · entry 1 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,586,626 Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:44 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | OtherPromissory Note due 9/16/2025 · Derivative | 240,000 | Not disclosed Strike: $0.29 | Not disclosed |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · derivative · entry 7 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,000 shares Expires not disclosed F3 · kind: Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above. F4 · shares: Represent shares previously issuable upon maturity of the Promissory Note due 9/16/2025. F3 · price: Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above. F3 · derivative.exercise_date: Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above. F3 · derivative.expiration_date: Promissory Note due 9/16/2025 surrendered for cancellation in exchange for shares of common stock referred to in footnote (1) above. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:44 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | OtherCommon stock, $0.001 par value | 4,447,426 | $0.29 | $1,289,753.54 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 6 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,619,126 F2 · kind: The shares shown were issued in exchange for principal and accrued interest under the promissory note of the Issuer held by the reporting person referred to in footnote (2), below, which promissory note was surrendered by the reporting person for cancellation. Read SEC document |
| December 15, 2023 Filed Dec 20, 2023 00:44 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | SaleCommon stock, $0.001 par value | 6,000 | $0.11 | $660.00 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 5 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,700 Read SEC document |
| September 05, 2023 Filed Dec 20, 2023 00:44 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,700 | $0.15 | $255.00 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 4 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,700 Read SEC document |
| August 30, 2023 Filed Dec 20, 2023 00:44 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 20,000 | $0.15 | $3,000.00 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 3 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,000 Read SEC document |
| August 25, 2023 Filed Dec 20, 2023 00:44 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 92,100 | $0.27 | $24,867.00 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 2 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.20 to $0.27, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 19:34 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | GrantOptions · Derivative | 100,000 | $4.50 Strike: $4.50 | $450,000.00 |
DisclosureSEC source: 0001209191-23-003468 · doc4.xml · derivative · entry 1 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-11 F1 · derivative.exercise_date: The options vest in four equal installments as of the last day of each quarter beginning on March 31, 2023 Read SEC document |
| October 09, 2022 Filed Dec 20, 2023 00:44 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 25,400 | $0.11 | $2,794.00 |
DisclosureSEC source: 0001209191-23-059268 · doc4.xml · nonDerivative · entry 1 Lim Seah H. · CIK 0001949484 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,900 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.